Able Sciences
RNA-based Off the Shelf Immune Cells for Cell Therapies
* Data source: Crunchbase
- Founded
- 2023
- Employees*
- 2-10
- Funding to Date*
- $275,000
- Website
- ablesciences.com
"With our proprietary RNA we create affordable durable cell therapy, with a unique multivalent approach that turns a single treatment into unprecedented combination therapy"
Nobody else has been able to get express multiple kill signals in cell therapy in a single step
Able Sciences, Inc. (Able) is deploying a leading-edge RNA technology platform to develop highly differentiated off-the-shelf, cost-effective cell therapies leading with allogeneic NK cells to cure Solid Cancers and Autoimmune Disorders.
More Companies
